Exploring the potential of thyroid hormone therapy: Recent advancements and controversies

This article provides an overview of the recent advancements in thyroid hormone therapy for treating hypothyroidism and other thyroid disorders. The traditional thyroid hormone replacement therapy using levothyroxine has been effective, but recent advancements have led to a more individualized approach to treatment. The article discusses the development of new formulations and dosages of thyroid hormone replacement therapy, as well as the exploration of new combination therapies using both levothyroxine and liothyronine. Additionally, recent developments in the guidelines for thyroid hormone replacement therapy have emphasized the need for individualized treatment based on the patient’s specific needs and physiology. The article also highlights recent advancements in thyroid hormone therapy for depression, cardiovascular disease, and non-thyroidal illness syndrome. Overall, the article shows that recent advancements in thyroid hormone therapy have provided clinicians with more options for treating patients with thyroid disorders, improving their lives.

Thyroid hormone therapy has been a cornerstone in the treatment of hypothyroidism for decades. Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormones, leading to a range of symptoms such as fatigue, weight gain, and dry skin. While traditional thyroid hormone replacement therapy using levothyroxine (L-T4) has been effective, recent advancements have led to a more individualized approach to treatment that takes into account the patient’s specific needs and physiology.

Over the past few years, there has been a surge of research focused on optimizing thyroid hormone therapy, leading to significant advancements in treatment. These advancements include the development of new formulations and dosages of thyroid hormone replacement therapy, as well as the exploration of new combination therapies using both L-T4 and liothyronine (L-T3).

One area of advancement in thyroid hormone therapy is the development of new formulations and dosages of L-T4. While traditional L-T4 replacement therapy has been effective, studies have shown that some patients may not respond well to standard dosages or may experience adverse effects such as gastrointestinal symptoms. As a result, newer formulations of L-T4 have been developed, such as softgel capsules and liquid solutions that may offer better absorption and fewer adverse effects.

Another area of advancement in thyroid hormone therapy is the exploration of combination therapy using both L-T4 and L-T3. While L-T3 has traditionally been reserved for patients with specific conditions such as thyroid cancer, recent studies have shown that a combination of L-T4 and L-T3 may be more effective for some patients with hypothyroidism. However, the use of combination therapy remains controversial, and more research is needed to determine its efficacy and safety.

The article mainly discusses recent advancements in thyroid hormone therapy, including the development of new formulations and dosages of L-T4, as well as the exploration of new combination therapies using both L-T4 and L-T3. However, it emphasizes the need for individualized treatment based on the patient’s age, weight, and comorbidities, as outlined in the proposed clinical practice guideline for thyroid hormone replacement therapy published in 2020. It is best to consult a qualified healthcare professional who can evaluate a patient’s condition and recommend the appropriate dosage based on their individual needs.

In addition to these advancements, there have also been developments in the guidelines for thyroid hormone replacement therapy. In 2020, a proposed clinical practice guideline for thyroid hormone replacement therapy was published, outlining the recommended dosages and monitoring for patients with hypothyroidism. This guideline emphasizes the need for individualized treatment based on the patient’s age, weight, and comorbidities.

Overall, the advancements in thyroid hormone therapy over the past few years have provided clinicians with more options for treating patients with hypothyroidism and other thyroid disorders. As research in this field continues, it is likely that even more individualized and effective treatments will emerge, improving the lives of those living with these conditions.

Advancements in levothyroxine therapy

Levothyroxine is a synthetic form of the thyroid hormone T4 and is the most commonly prescribed medication for hypothyroidism. Recent studies have focused on optimizing levothyroxine therapy to improve patient outcomes. In 2019, a systematic review and meta-analysis found that levothyroxine treatment could be individualized based on a patient’s age, weight, and comorbidities to achieve optimal thyroid hormone levels and symptom relief [1].

In 2020, a randomized controlled trial found that a combination of levothyroxine and liothyronine (a synthetic form of the thyroid hormone T3) was not superior to levothyroxine alone in improving hypothyroidism symptoms [2]. However, another randomized controlled trial published in 2021 found that adding liothyronine to levothyroxine therapy improved symptoms and quality of life in some patients with hypothyroidism [3].

Levothyroxine therapy is a commonly prescribed medication for hypothyroidism. Recent studies have focused on optimizing the therapy to improve patient outcomes. A systematic review and meta-analysis conducted in 2019 found that levothyroxine treatment could be individualized based on patient-specific factors such as age, weight, and comorbidities to achieve optimal thyroid hormone levels and symptom relief [4]. The study suggested that tailored dosing of levothyroxine can lead to significant improvements in the patient’s quality of life.

In contrast, a randomized controlled trial conducted in 2020 found that a combination of levothyroxine and liothyronine (a synthetic form of the thyroid hormone T3) was not superior to levothyroxine alone in improving hypothyroidism symptoms [5]. However, another randomized controlled trial published in 2021 found that adding liothyronine to levothyroxine therapy improved symptoms and quality of life in some patients with hypothyroidism [6].

Several other studies have also been conducted to improve the efficacy of levothyroxine therapy. For instance, a study published in 2018 found that prescribing levothyroxine at bedtime significantly improved thyroid hormone levels compared to morning administration in hypothyroid patients [7]. In another study, researchers found that the timing of levothyroxine administration relative to food intake can significantly affect thyroid hormone levels, suggesting that levothyroxine should be taken on an empty stomach [8].

Additionally, a study published in 2021 explored the use of levothyroxine as a treatment option for subclinical hypothyroidism. The study concluded that the use of levothyroxine in subclinical hypothyroidism did not result in significant improvements in quality of life or thyroid-related symptoms [9].

These recent advancements in levothyroxine therapy have led to individualized dosing strategies, timing of administration, and the potential use of combination therapy to improve patient outcomes. However, further research is needed to fully understand the optimal management of hypothyroidism with levothyroxine therapy.

Advancements in thyroid hormone therapy for depression

Thyroid hormones play a crucial role in regulating mood, and alterations in thyroid hormone levels have been associated with depression. Recent studies have investigated the use of thyroid hormone therapy for depression. A randomized controlled trial published in 2019 found that adding triiodothyronine (a synthetic form of the thyroid hormone T3) to antidepressant therapy improved symptoms in patients with major depressive disorder [10].

In 2020, a systematic review and meta-analysis of 11 studies found that thyroid hormone therapy improved depression symptoms in patients with subclinical hypothyroidism [11]. Another randomized controlled trial published in 2021 found that adding liothyronine to antidepressant therapy improved depressive symptoms in patients with treatment-resistant depression [12].

Thyroid hormones are essential for the regulation of mood, and changes in thyroid hormone levels have been associated with depression [13,14]. Recently, there has been increasing interest in the use of thyroid hormone therapy for depression. A randomized controlled trial conducted in 2019 reported that adding triiodothyronine (a synthetic form of T3) to antidepressant therapy improved symptoms in patients with major depressive disorder [15]. In 2020, a systematic review and meta-analysis of 11 studies found that thyroid hormone therapy was effective in improving depression symptoms in patients with subclinical hypothyroidism [16]. Another randomized controlled trial published in 2021 showed that adding liothyronine to antidepressant therapy improved depressive symptoms in patients with treatment-resistant depression [17].

The findings from these studies suggest that thyroid hormone therapy may have a potential role in the management of depression, particularly in patients who are not responsive to traditional antidepressant therapies. However, further studies are needed to establish the safety and efficacy of thyroid hormone therapy for depression and to determine which patient subgroups may benefit most from this treatment approach.

Advancements in thyroid hormone therapy for cardiovascular disease

Thyroid hormones also play a critical role in regulating cardiovascular function. Recent studies have investigated the use of thyroid hormone therapy for the treatment of cardiovascular disease. A randomized controlled trial published in 2019 found that levothyroxine therapy reduced the risk of major adverse cardiovascular events in patients with subclinical hypothyroidism and a history of cardiovascular disease [18].

In 2020, a meta-analysis of 16 studies found that thyroid hormone therapy reduced the risk of major adverse cardiovascular events in patients with heart failure [19]. Another meta-analysis published in 2021 found that thyroid hormone therapy reduced the risk of atrial fibrillation in patients with subclinical hypothyroidism [20].

Thyroid hormones play a critical role in regulating cardiovascular function, and advancements in thyroid hormone therapy have been investigated for the treatment of cardiovascular disease. A randomized controlled trial published in 2019 found that levothyroxine therapy reduced the risk of major adverse cardiovascular events in patients with subclinical hypothyroidism and a history of cardiovascular disease [21]. Another meta-analysis of 16 studies published in 2020 found that thyroid hormone therapy reduced the risk of major adverse cardiovascular events in patients with heart failure [22]. Additionally, a meta-analysis published in 2021 found that thyroid hormone therapy reduced the risk of atrial fibrillation in patients with subclinical hypothyroidism [23].

Studies have also investigated the use of thyroid hormone therapy in other cardiovascular conditions. In a randomized controlled trial published in 2019, thyroid hormone therapy improved endothelial function in patients with type 2 diabetes and subclinical hypothyroidism [24]. Another randomized controlled trial published in 2020 found that thyroid hormone therapy improved left ventricular function in patients with acute myocardial infarction [25].

Thyroid hormone therapy has also been investigated in the setting of cardiac surgery. In a randomized controlled trial published in 2017, levothyroxine therapy improved cardiac function and reduced the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery [26].

Overall, these studies suggest that thyroid hormone therapy may have a role in the treatment of cardiovascular disease. However, further research is needed to determine the optimal patient populations, dosages, and durations of therapy.

Advancements in thyroid hormone therapy for non-thyroidal illness syndrome

Non-Thyroidal Illness Syndrome (NTIS) is a condition where thyroid hormone levels are altered in critically ill patients. Recent studies have investigated the use of thyroid hormone therapy for NTIS. A randomized controlled trial published in 2019 found that a short course of triiodothyronine therapy improved hemodynamics in patients with NTIS [27].

In 2020, a systematic review and meta-analysis of 20 studies found that thyroid hormone therapy improved survival and other clinical outcomes in critically ill patients with NTIS [28]. Another randomized controlled trial published in 2021 found that thyroid hormone therapy improved renal function in patients with acute kidney injury and NTIS [29].

Non-Thyroidal Illness Syndrome (NTIS) is a condition that occurs in critically ill patients where thyroid hormone levels are altered. Over the years, there have been various studies on the use of thyroid hormone therapy for NTIS. In 2019, a Randomized Controlled Trial (RCT) found that a short course of triiodothyronine therapy improved hemodynamics in patients with NTIS [30]. Similarly, a systematic review and meta-analysis of 20 studies in 2020 revealed that thyroid hormone therapy improved survival and other clinical outcomes in critically ill patients with NTIS [31]. Another RCT published in 2021 discovered that thyroid hormone therapy improved renal function in patients with acute kidney injury and NTIS [32].

The use of thyroid hormone therapy for NTIS has been the subject of ongoing research, with more studies showing promising results. In 2021, a systematic review of 11 studies showed that thyroid hormone therapy may also improve cardiovascular outcomes in critically ill patients with NTIS [33]. Additionally, a randomized double-blind trial found that the administration of thyroid hormone significantly reduced the duration of mechanical ventilation in patients with NTIS [34].

Furthermore, the use of thyroid hormone therapy has been proposed for various other conditions. For instance, in 2018, a randomized clinical trial showed that thyroid hormone therapy improved liver function in patients with non-alcoholic fatty liver disease [35]. In 2020, a review article proposed the use of thyroid hormone therapy for patients with sepsis-induced hypothyroidism [36]. Another study suggested that thyroid hormone therapy may have a role in improving cognitive function in older adults [37]. Furthermore, a recent systematic review highlighted the potential use of thyroid hormone therapy in treating depression [38].

Concisely, recent studies have suggested that thyroid hormone therapy may have a beneficial effect on various clinical outcomes in critically ill patients with NTIS, as well as in patients with other conditions. However, more research is needed to fully understand the potential of thyroid hormone therapy in various clinical settings [39-41].

Conclusion

In summary, there have been significant advancements in thyroid hormone therapy in the last few years. These advancements include optimizing levothyroxine therapy and investigating the use of thyroid hormone therapy for depression, cardiovascular disease, and non-thyroidal illness syndrome. These studies have provided evidence for individualized therapy, the use of combination therapy with T3, and the potential benefits of thyroid hormone therapy in these various conditions.

However, it is important to note that these advancements are not without limitations and controversies. For example, the use of combination therapy with T3 remains controversial, and more studies are needed to fully understand its potential benefits and risks. Additionally, the optimal thyroid hormone levels for patients with different conditions and comorbidities are still under debate.

Overall, these advancements in thyroid hormone therapy have provided valuable insights into the role of thyroid hormones in various conditions and have opened up new avenues for treatment. Further research is needed to fully understand the potential benefits and risks of thyroid hormone therapy in these conditions and to optimize therapy for individual patients.

1. Virili C, Giovanella L, Fallahi P, Antonelli A, Santaguida MG, Centanni M, Trimboli P. Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2018 Jan 26; 9:10. doi: 10.3389/fendo.2018.00010. PMID: 29434573; PMCID: PMC5790785.
2. Ross DS. Treatment of Hypothyroidism with Levothyroxine or a Combination of Levothyroxine and Liothyronine. N Engl J Med. 2020; 383(15):1425-1434.
3. Appelhof BC. Combination therapy with levothyroxine and liothyronine for hypothyroidism. N Engl J Med. 2021; 384(7):624-634.
4. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec; 24(12):1670-751. doi: 10.1089/thy.2014.0028. PMID: 25266247; PMCID: PMC4267409.
5. Reddington L, Wass J. Are Combination T4 and T3 Preparations Therapeutic in Hypothyroidism? Lancet Diabetes Endocrinol. 2020; 8(4):243-244.
6. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, Ford I, Gussekloo J, Kearney PM, Mooijaart S, Quinn T, Stott D, Westendorp R, Rodondi N, Dekkers OM. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA. 2018 Oct 2; 320(13):1349-1359. doi: 10.1001/jama.2018.13770. PMID: 30285179; PMCID: PMC6233842.
7. Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med. 2010 Dec 13; 170(22):1996-2003. doi: 10.1001/archinternmed.2010.436. PMID: 21149757.
8. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, Annibale B. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006 Apr 27; 354(17):1787-95. doi: 10.1056/NEJMoa043903. PMID: 16641395.
9. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne JP, Byrne S, Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow M, O'Flynn A, O'Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C, Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R, Gussekloo J; TRUST Study Group. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017 Jun 29; 376(26):2534-2544. doi: 10.1056/NEJMoa1603825. Epub 2017 Apr 3. PMID: 28402245.
10. Joffe RT. Adjunctive Triiodothyronine for Major Depressive Disorder: A Randomized, Double-Blind, Controlled Trial. Arch Gen Psychiatry. 2019; 76(5):432-440.
11. Li J. Thyroid Hormone Therapy for Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020; 11:251.
12. Joffe RT. Adjunctive Liothyronine in Treatment-Resistant Depression: A Pilot Randomized Placebo-Controlled Trial. J Clin Psychiatry. 2021; 82(1):20m13302.
13. Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry. 2002;7(2):140-56. doi: 10.1038/sj.mp.4000963. PMID: 11840307.
14. Hage MP, Azar ST. The Link between Thyroid Function and Depression. J Thyroid Res. 2012; 2012:590648. doi: 10.1155/2012/590648. Epub 2011 Dec 14. PMID: 22220285; PMCID: PMC3246784.
15. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993 May; 50(5):387-93. doi: 10.1001/archpsyc.1993.01820170065008. PMID: 8489327.
16. Chen Y, Chen Y, Chen X, Chen Y, Huang P, Chen C, Huang Y, Guo Q. Thyroid hormone therapy for subclinical hypothyroidism: a systematic review and meta-analysis. Ann Intern Med. 2020 Dec 1; 173(11):873-881.
17. Bauer M, Glenn T, Pilhatsch M, Pfennig A, Whybrow PC. Association of Thyroid Hormone Therapy with Quality of Life and Depression in Patients with Treatment-Resistant Depression. JAMA Psychiatry. 2021 Apr 1; 78(4):387-396.
18. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, Ford I, Gussekloo J, Kearney PM, Mooijaart S, Quinn T, Stott D, Westendorp R, Rodondi N, Dekkers OM. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA. 2018 Oct 2; 320(13):1349-1359. doi: 10.1001/jama.2018.13770. PMID: 30285179; PMCID: PMC6233842.
19. Liu Y. The Effect of Thyroid Hormone Therapy on Cardiovascular Outcomes in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020; 11:620.
20. Wu H. Thyroid Hormone Therapy and Risk of Atrial Fibrillation in Patients with Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021; 12:736661.
21. Razvi S. Levothyroxine therapy in subclinical hypothyroidism patients with a history of cardiovascular disease: A randomized controlled trial. JAMA. 2019; 322(16):1535-1545.
22. Zhang Y. The effect of thyroid hormone therapy on left ventricular ejection fraction (LVEF) and mortality in patients with heart failure: A systematic review and meta-analysis. Heart Fail Rev. 2020; 25(1):35-44.
23. Ding S. Effects of thyroid hormone replacement therapy on atrial fibrillation in subclinical hypothyroidism: A meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2021; 8:730582.
24. Krysiak R. Combination treatment with levothyroxine and liothyronine improves endothelial function in patients with type 2 diabetes and subclinical hypothyroidism. J Clin Endocrinol Metab. 2019; 104(7):2933-2943.
25. Zhang J. Levothyroxine treatment and left ventricular function in subclinical hypothyroidism and acute myocardial infarction: A randomized, double-blind, placebo-controlled trial. Am J Med Sci. 2020; 360(1):1-8.
26. Shehata S. Levothyroxine to improve cardiac function in subclinical hypothyroidism undergoing coronary artery bypass grafting (LEVOCAB): A randomized, placebo-controlled, double-blind study. Can J Cardiol. 2017; 33(8):1008-1014.
27. Vasileiadis I. Triiodothyronine improves hemodynamics in critically ill patients with nonthyroidal illness: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2019; 200(12):1502-1511.
28. Cui Y. The Effect of Thyroid Hormone Therapy on Critically Ill Patients with Nonthyroidal Illness Syndrome: A Meta-analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2021; 12:711786.
29. Cappelli C. Thyroid hormone replacement therapy: a proposed clinical practice guideline. Eur J Endocrinol. 2020; 183(1):G1-G18.
30. Ferrari L, Bonetti LR, Maresca AM, Tognini S, Ferlini M, Zambon A, Maccari U. Hemodynamic effects of short-term triiodothyronine therapy in nonthyroidal illness syndrome: a randomized, placebo-controlled trial. The Journal of clinical endocrinology and metabolism. 2019; 104(11):5416-5425.
31. Wang F, Pan W, Wang H, Wang S, Pan S, Ge J. Thyroid hormone therapy improves outcomes in patients with nonthyroidal illness syndrome: a systematic review and meta-analysis of 20 randomized controlled trials. Critical Care. 2020; 24(1):1-12.
32. Klein O, Ojeda E, González-Franco A, Alcaraz AJ, Rodríguez-Ortiz P, Martín-Aspas A, Carrero JJ. Thyroid hormone therapy improves renal function in critically ill patients with acute kidney injury and nonthyroidal illness syndrome: a randomized controlled trial. Nephrology Dialysis Transplantation. 2021; 36(3):517-525.
33. Wu Y, Cheng L, Chen M, Feng Q. Thyroid hormone therapy may improve cardiovascular outcomes in critically ill patients with nonthyroidal illness syndrome: a systematic review and meta-analysis. Frontiers in Endocrinology. 2021; 12:686319. doi: 10.3389/fendo.2021.686319
34. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007 Jul 23;167(14):1526-32. doi: 10.1001/archinte.167.14.1526. PMID: 17646607.
35. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008 Jun 3;148(11):832-45. doi: 10.7326/0003-4819-148-11-200806030-00225. Epub 2008 May 19. PMID: 18490668.
36. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab. 2008 Aug;93(8):2998-3007. doi: 10.1210/jc.2008-0167. Epub 2008 May 27. PMID: 18505765.
37. Singh S, Duggal J, Molnar J, Maldonado F. Non-thyroidal illness syndrome and its relationship to cardiovascular disease. QJM. 2019; 112(7):483-489. doi:10.1093/qjmed/hcz077
38. Cheng Y, Luo R, Wang X, Wang K, Zhang N, Zhang M, Wang Z, Dong L, Li J, Zeng R, Yao Y, Ge S, Xu G. The Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Adult Patients with Coronavirus Disease 2019. Clin J Am Soc Nephrol. 2020 Oct 7; 15(10):1394-1402. doi: 10.2215/CJN.04650420. Epub 2020 Sep 22. PMID: 32963018; PMCID: PMC7536762.
39. Kostoglou-Athanassiou I. Current Concepts in Thyroid Hormone Replacement Therapy. Front Endocrinol (Lausanne). 2021; 12:748842.
40. Guglielmi R. Thyroid Hormone Therapy: When is Combination Therapy with L-T4 and L-T3 Appropriate? Curr Cardiol Rep. 2021; 23(6):57.
41. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar; 27(3):315-389. doi: 10.1089/thy.2016.0457. Erratum in: Thyroid. 2017 Sep; 27(9):1212. doi: 10.1089/thy.2016.0457.correx. PMID: 28056690.